Research Analysts Set Expectations for Edap Tms Q2 Earnings

Edap Tms S.A. (NASDAQ:EDAP) – Equities researchers at HC Wainwright decreased their Q2 2026 earnings estimates for shares of Edap Tms in a research report issued to clients and investors on Friday, May 8th. HC Wainwright analyst S. Ramakanth now forecasts that the medical equipment provider will post earnings per share of ($0.17) for the quarter, down from their prior forecast of ($0.16). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Edap Tms’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Edap Tms’ Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.78) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.17) EPS and Q4 2027 earnings at ($0.07) EPS.

Edap Tms (NASDAQ:EDAP) last issued its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $20.48 million during the quarter, compared to the consensus estimate of $19.46 million. Edap Tms had a negative net margin of 41.47% and a negative return on equity of 137.61%.

Separately, Wall Street Zen downgraded shares of Edap Tms from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Edap Tms has an average rating of “Hold” and an average price target of $6.00.

Edap Tms Stock Performance

NASDAQ:EDAP opened at $4.17 on Tuesday. The company has a market capitalization of $156.29 million, a PE ratio of -5.15 and a beta of -0.10. The company has a 50 day simple moving average of $3.70 and a two-hundred day simple moving average of $3.39. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34. Edap Tms has a fifty-two week low of $1.21 and a fifty-two week high of $5.05.

Institutional Trading of Edap Tms

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Financial Planning Navigators CORP acquired a new stake in shares of Edap Tms during the 4th quarter worth approximately $33,000. Rock Springs Capital Management LP grew its position in shares of Edap Tms by 1.3% during the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider’s stock worth $4,233,000 after buying an additional 16,500 shares during the period. Kovack Advisors Inc. acquired a new stake in shares of Edap Tms during the 4th quarter worth approximately $53,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Edap Tms during the 1st quarter worth approximately $38,000. Finally, Flax Pond Capital LLC acquired a new stake in shares of Edap Tms during the 4th quarter worth approximately $2,623,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

About Edap Tms

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.